Finanzen von Cosmos Health Inc (COSM)COSMCosmos Health Inc

Cosmos Health Inc (COSM) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Wholesale, accounting for 94.2% of total sales, equivalent to $16.89M. Other significant revenue streams include Nutraceutical and pharmaceuticals and Pharma manufacturing. Understanding this composition is critical for investors evaluating how COSM navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Cosmos Health Inc maintains a gross margin of 6.12%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -15.41%, while the net margin is -32.06%. These profitability ratios, combined with a Return on Equity (ROE) of -104.00%, provide a clear picture of how effectively COSM converts its operational activities into shareholder value.

In the context of the broader market, COSM competes directly with industry leaders such as ALLR and ABVC. With a market capitalization of $24.43M, it holds a leading position in the sector. When comparing efficiency, COSM's gross margin of 6.12% stands against ALLR's 100.00% and ABVC's N/A. Such benchmarking helps identify whether Cosmos Health Inc is trading at a premium or discount relative to its financial performance.

Cosmos Health has shown a strong revenue growth of 28% in Q2 2026, reaching $18.99 million, despite facing a net loss of $6.09 million, indicating the company is expanding its market presence but still struggling with profitability.